Page 246 - Health Medical Pharma
Glenmark gets USFDA nod for multiple sclerosis medication
Glenmark Pharmaceuticals Friday said it has received approval from the US health regulator for Teriflunomide tablets used to treat multiple sclerosis. The approved product is generic version of Sanofi-Aventis US' Aubagio. Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Teriflunomide tablets in the strengths of 7 mg and 14 mg, the company said in a BSE filing. Glenmark said with respect to 180-day generic drug exclusivity, it was one of the applicants to submit a substantially complete first abbreviated new drug application (ANDA) for Teriflunomide tablets. "Therefore, with this approval, Glenmark is eligible for 180 days of shared generic drug exclusivity for Teriflunomide Tablets, 7 mg and 14 mg," it added. Citing IQVIA sales data for the 12-month period ending September 2018, the company said the Aubagio tablets market achieved annual sales of approximately USD 1.6 billion. The company's current portfolio ..
Twitter use influenced by social schedules: Study
Twitter usage largely mirrors daily work schedules and school calendars, an analysis of data on the social networking site from the US shows. The data reflects the amount of "social jet lag" caused when social demands make people wake up much earlier than their biological rhythms would prefer, said researchers from the University of Chicago in the US. The study, published in the journal Current Biology, analysed the Twitter activity of more than 246,000 users from 2012 to 2013 to look for daily patterns of usage. The tweets were tagged with geographic location data from more than 1,500 counties in all 50 states and the District of Columbia. The data serve as a proxy for people's sleep and wake times, a public record of sorts that shows when someone is awake and still using Twitter. Across the US, there is a daily slowdown in tweets at night when most people go to bed. The researchers saw that this nighttime lull shifts to later times on weekends relative to weekdays, a phenomenon they
Cannabis allergy may worsen asthma symptoms in children
It is well known that second hand smoke from cigarettes is a risk to anyone who suffers from asthma. But a new research showed that it's possible for both children and adults with uncontrolled asthma to find their symptoms worsening due to cannabis allergy and exposure to marijuana smoke.A new research, conducted at the American College of Allergy, Asthma, and Immunology, analysed the livelihood of people smoking marijuana and how it affects the health of people around them."A 6-year-old boy suffering from severe asthma had family members who frequently smoked marijuana in the house," said Bryce Hoffman, lead author of the study. "Even though family members didn't smoke marijuana in the same room as the child, he was exposed to traces of smoke and plant material. It was not clear why his asthma was so severe and not responding to aggressive asthma therapies until we determined he was allergic to cannabis. After the cannabis was removed from the house, his asthma improved."In addition .
Study suggests way to treat severe eczema
Suffering from severe eczema? It may best be treated by allergy shots, according to researchers.A medically-challenging case being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting found that allergy shots provided significant benefits to the eczema symptoms suffered by a 48-year-old man."The man had suffered with severe eczema since childhood," said allergist Anil Nanda, lead author of the paper. "He had tried many previous therapies for years including mild and high strength topical corticosteroid cream, as well as other topical anti-inflammatory creams and topical moisturizer creams. Biologic therapy has been available to treat eczema for about a year and-a-half but was not yet a treatment option at the time we saw this man. We thought allergy shots might be beneficial because he also had multiple allergies."Atopic dermatitis is an allergic disease, and patients who have it often also have other types of allergies. Symptoms of ...
Dr Reddys Laboratories Ltd spurts 0.36%, up for five straight sessions
The stock is quoting at Rs 2470.55, up 0.36% on the day as on 12:44 IST on the NSE. Dr Reddys Laboratories Ltd is up 6.37% in last one year as compared to a 3.8% gain in NIFTY and a 1.55% gain in the Nifty Pharma.
Know how anti-malaria drugs help in treating cancer
According to previous researches, anti-malaria drugs known as chloroquines were repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor.Now, researchers from the University of Pennsylvania explained that an enzyme called PPT1 - opens up a new pathway for potential cancer treatments. The findings appeared in the Journal of Cancer Discovery.The team also used CRISPR/Cas9 gene editing to remove PPT1 from cancer cells in the lab and found that eliminating it slows tumor growth. They detailed a potent chloroquine, known as DC661, that can take advantage of this new treatment pathway."The discovery of this target is critical because chloroquines are currently being evaluated in clinical trials all over the world, and this knowledge fundamentally changes the way we look at those trials," said the study's co-senior author Ravi K. Amaravadi.PPT1 is an enzyme which helps in controlling both the mechanistic target of
Shilpa Medicare advances after securing USFDA approval
Shilpa Medicare gained 3.74% to Rs 388 at 12:09 IST on BSE after the company's ANDA for Dimethyl Fumarate Delayed Release Capsules was granted tentative approval by FDA.
Shilpa Medicare gets tentative USFDA nod for multiple sclerosis drug
Shilpa Medicare Thursday said it has received tentative approval from the US health regulator for Dimethyl Fumarate delayed release capsules, used for treatment of relapsing forms of multiple sclerosis. The company's abbreviated new drug application (ANDA) for Dimethyl Fumarate delayed release capsules in the strengths of 120 mg and 240 mg has been granted tentative approval by the United States Food and Drug Administration (USFDA), Shilpa Medicare said in a BSE filing. Dimethyl Fumarate delayed release capsules is a generic of Tecfidera, it added. Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Dimethyl Fumarate delayed release capsules is approximately USD 3.46 billion. Shares of Shilpa Medicare were trading 3.92 per cent up at Rs 388.65 apiece on BSE.
Shilpa Medicare gets tentative ANDA approval for Dimethyl Fumarate DR Capsules
Dimethyl Fumarate Delayed Release Capsules 120 mg & 240 mg is a generic of TECFIDERA, used in the treatment of patients with relapsing forms of multiple sclerosis.
Glenmark Pharmaceuticals gets USFDA approval for Teriflunomide Tablets
With respect to 180-day generic drug exclusivity, we note that Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Teriflunomide Tablets, 7 mg and 14 mg, with a paragraph IV certification. Therefore, with this approval, Glenmark is eligible for 180 days of shared generic drug exclusivity for Teriflunomide Tablets, 7 mg and 14 mg.
Swine flu claims two more lives in Hyderabad
The occurrence of swine flu is gaining momentum as two more people have lost their lives in Hyderabad's Gandhi Hospital, thus taking the death toll to nine."9 people out of the 43 who tested positive for swine flu have died so far. People between 45 - 65 years of age are affected more in the state. At present, 6 people who tested positive for swine flu have been admitted at Gandhi hospital, while 6 more are suspected to have swine flu," Shravan Kumar, Superintendent of Gandhi Hospital, told ANI.Kumar further said a disaster ward has been arranged specially for swine flu cases, comprising 20 beds and 10 ventilators reserved for swine flu patients. Pharmacology department doctors are taking care of swine flu patients in Gandhi Hospital, he added.In the wake of the sudden rise in swine flu cases in the city, doctors have advised locals to carry face masks and maintain hygiene. Individuals have also been advised to maintain some distance while in proximity to patients.Swine flu is an ...
20 years after liver transplant, man training to become doctor
Now 21, Sanjay Kandasamy did not have an ordinary childhood. At just 20 months of age, he had a part of his father's liver transplanted into him in November 1998. In doing so, Sanjay and his doctors created history in the annals of Indian medicine as the country's first successful liver transplant surgery, Indraprastha Apollo hospitals said in statement. Remarkably, not only has Sanjay done exceedingly well, he is now training to be a doctor himself. On the 20th anniversary of the operation that changed the face of medical sciences in India, the hospital showcased the evolution that liver transplants have gone through over the last two decades. Dr Preetha Reddy, vice chairperson of the Apollo Hospitals Group, said liver disease is a major cause for concern in the country with as many as two lakh people dying from it every year. While around 1,800 liver transplants are done annually, as many as 20,000 people need a liver transplant at any given point. "The fact is around 10 lakh people
Hot bath may improve inflammation, metabolism: Study
If you are unable to exercise, a hot water treatment may help improve inflammation and blood sugar (glucose) levels, particularly in overweight men, suggests a new study.
Migraines that affect vision may increase irregular heartbeat risk
People who experience migraine with visual aura may have an increased risk of irregular heartbeat, and as a result stroke, say researchers including one of an Indian-origin.
Merck Foundation announces winners for Merck Diabetes Award
Merck Foundation, the philanthropic arm of Merck KGaA Germany marked 'World Diabetes Day 2018' by announcing the winners of Merck Diabetes Awards 2017 and call for application for Merck Diabetes Award 2018."Merck Foundation launched 'Merck Diabetes Award' in 2016 in more than 30 African and Asian universities in partnership with health ministries. The aim is to build a platform of diabetes experts across the globe.This year we discussed the concept of involving our partners from First ladies and ministries of health in 10 African countries in selecting the winners and the candidates for this valuable diploma so that they can establish diabetes clinics across the counties in each country, this will be a strong milestone of improving access to quality and equitable diabetes care, not only in the capital but nationwide" emphasizes Dr. Rasha Kelej, CEO of Merck Foundation.Winners of the Merck Diabetes Award 2017 were announced this year. The award attracted over 500 concept submission ...
Is emotional intelligence new criteria for hiring?
Besides cognitive skills and personality, assessing a candidates' level of emotional intelligence is equally important for a job interview, suggests a new study.
Weightlifting less than an hour a week may cut stroke risk
Indulging in weightlifting for less than an hour a week may reduce your risk for a heart attack or stroke by 40 to 70 per cent, suggests a new study.
Lupin gains after FDA approval for Decitabine
Lupin rose 1.15% to Rs 851 at 14:41 IST on BSE after the company announced it has received FDA approval for Decitabine for Injection, 50 mg/vial, Single-Dose Vial.
Lupin gets USFDA nod for myelodysplastic syndrom drug
Drug firm Lupin Thursday said it has received approval from the US health regulator to market Decitabine for injection, used for the treatment of myelodysplastic syndromes (MDS). The company has received an approval from the United States Food and Drug Administration (USFDA) to market Decitabine for Injection, 50 mg/vial, single-dose vial, Lupin said in a statement. Decitabine -- the generic version of Otsuka's Dacogen for Injection, 50 mg/vial -- had annual sales of approximately USD 135.9 million in the US, it said. Shares of Lupin were trading at Rs 852.00 apiece on the BSE, up 1.27 per cent from their previous close.
Procter & Gamble Hygiene and Health Care Ltd eases for fifth straight session
The stock is quoting at Rs 9496, down 0.02% on the day as on 13:21 IST on the NSE. Procter & Gamble Hygiene and Health Care Ltd tumbled 7.33% in last one year as compared to a 4.17% rally in NIFTY and a 13.94% fall in the Nifty FMCG index.